personalised Diabetes Management using lOw-cost Needle-free multiple-biomarkers monitoring Device

Project Information

DiaMOND

Grant agreement ID: 811792

DOI 10.3030/811792

Project closed

EC signature date 10 May 2018

Start date 1 July 2018

End date 30 June 2021

Funded under

• INDUSTRIAL LEADERSHIP - Innovation In SMEs

Total cost € 4 519 408,75

EU contribution € 2 493 273,13

Coordinated by

INDIGO DIABETES
Belgium

Objective

"""Diabetes is the #1 health challenge of the 21st century. Continuous Glucose Monitoring or CGM ($1.25B market in 2016, growing 29%/yr) is today’s cornerstone of “diabetes self-management” and the most effective solution to reduce the economic and societal burden of diabetes. But the shortcomings of current CGMs hinder their wider adoption: high cost, unsatisfactory predictability of severe events, and poor user comfort. The DiaMOND project will remove these barriers by bringing needle-free, low-cost Continuous Diabetes Monitoring to market. DiaMOND is specifically geared at extending Indigo’s current CGM with reliable severe clinical event prediction and a great user experience; demonstrating the reliability in a first-in-man trial; creating market acceptance by involving Key Opinion Leaders; and obtaining reimbursement. Indigo will be ready for a large pivotal clinical study and CE marking after completing the DiaMOND project. DiaMOND will accelerate Indigo’s CDM market access by 2-3 years."""

Fields of science (EuroSciVoc)

CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: https://op.europa.eu/en/web/eu-vocabularies/euroscivoc.

• medical and health sciences › clinical medicine › endocrinology › diabetes
• natural sciences › biological sciences › biochemistry › biomolecules › lipids
• engineering and technology › electrical engineering, electronic engineering, information engineering › electronic engineering › sensors
• medical and health sciences › medical biotechnology › tissue engineering › artificial pancreas › continuous glucose monitors

You need to log in or register to use this function

Programme(s)

• H2020-EU.2.3. - INDUSTRIAL LEADERSHIP - Innovation In SMEs Main Programme
• H2020-EU.3. - PRIORITY 'Societal challenges
• H2020-EU.2.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies

Topic(s)

• EIC-SMEInst-2018-2020 - SME instrument

Call for proposal

H2020-EIC-SMEInst-2018-2020

See other projects for this call

Sub call

H2020-SMEInst-2018-2020-2

Funding Scheme

SME-2 - SME instrument phase 2

Coordinator

INDIGO DIABETES

• Net EU contribution: € 2 493 273,13
• Address: BOLLEBERGEN 2B/30 ; 9052 Gent ; Belgium
• SME The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed. Yes:
  Region
  Vlaams Gewest › Prov. Oost-Vlaanderen › Arr. Gent
• Region: Vlaams Gewest › Prov. Oost-Vlaanderen › Arr. Gent
• Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Total cost: € 4 519 408,75